# Evaluating the Impact of EnteraGam In People With COVID-19

> **NCT04682041** · NA · COMPLETED · sponsor: **Entera Health, Inc** · enrollment: 200 (actual)

## Conditions studied

- Covid19

## Interventions

- **DIETARY_SUPPLEMENT:** Bovine Plasma-Derived Immunoglobulin Concentrate
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04682041
- **Lead sponsor:** Entera Health, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2021-12-20
- **Final completion:** 2022-02-21
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04682041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04682041, "Evaluating the Impact of EnteraGam In People With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04682041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*